key: cord-0988496-jug3cei8 authors: Morales-Ortega, Alejandro; Bernal-Bello, David; Llarena-Barroso, Cristina; Frutos-Pérez, Begoña; Duarte-Millán, Miguel Ángel; de Viedma-García, Vanessa García; Farfán-Sedano, Ana Isabel; Canalejo-Castrillero, Eduardo; Ruiz-Giardin, José Manuel; Ruiz-Ruiz, Justo; Martín-López, Juan Víctor San title: Imatinib for COVID-19: A case report date: 2020-06-27 journal: Clin Immunol DOI: 10.1016/j.clim.2020.108518 sha: 05dbfaad92364aa6dccc08e0cefe2d24bddc104b doc_id: 988496 cord_uid: jug3cei8 nan On March 12, a 38-year-old woman was admitted to our department with a 6-day history of fever up to 39ºC, arthralgia, malaise and cough. Her blood pressure, heart rate and respiratory rate were all normal. Her temperature was 37.1ºC and oxygen saturation was 96% while she was breathing ambient air. Physical examination only revealed minimal wheezing on ches t auscultation. Laboratory results showed a mild elevation of C-reactive protein (CRP) and lactate dehydrogenase (LDH) levels, and a normal lymphocyte count (Table 1) . Chest X-ray confirmed bilateral pneumonia. Polymerase chain reaction tes t for SARS-CoV-2 in nasopharyngeal swab was positive, so treatment with HCQ and LPV/r , as well as empiric therapy with ceftriaxone, was initiated in accordance with hospital protocol . The patient reported initial improvement; however, on March 15 (day 9 of symptoms) fever recurred and supplemental oxygen by nasal cannula at a rate of 3 liters per minute was required. Furthermore, both an increase in CRP levels ( Table 1 ) and radiological deterioration were observed ( Fig. 1, a) . These clinical changes suggested that the disease was progressing to an early phase of a hyperinflammatory state despite treatment with HCQ and LPV/r; thus, after assessing the safety profile of imatinib [3] and reviewing previous publications about its antiviral and immunomodulatory properties, we considered that this drug may have potentially beneficial effects in such clinical scenario. Hence, informed c ons ent was obtained and imatinib (400mg once daily) was added on day 12 of symptoms, while ceftriaxone was interrupted since there was no evidence of concurrent bacterial infection. Three days later the fever disappeared, supplemental oxygen was discontinued and radiological stability of pulmonary opacities was confirmed. Moreover, improvement in laboratory parameters was observed on day 5 of imatinib s o it was stopped and the patient was subsequently discharged on day 16 of symptoms after also completing 9 days of HCQ and LPV/r. She remained asymptomatic on April 11 (20 days after discharge), her blood tests were then normal (Table 1) and pulmonary opacities had almost disappeared (Fig. 1, b) . Although developed targeting the oncogenic fusion protein BCR-ABL, imatinib is able to inhibit other tyrosine kinases such as c-KIT, platelet-derived growth factor receptor and Abelson kinases (ABL) type 1 and 2 [4] ; therefore, it has been postulated that the biological activity of this drug is not restricted to anticancer effects. In this regard, immunomodulatory properties of imatinib have been reported. Murine models of sepsis and acute lung injury have suggested a protective role of this drug by reduc i ng J o u r n a l P r e -p r o o f Journal Pre-proof pulmonary edema, preventing histological damage and improvi ng endothelial barrier dysfunction, probably through attenuation of proinflammatory cytokine release including interleukin -6 and tumor necrosis factor-alpha [4, 5] . These effects over inflammatory activation might be mediated by the inhibition of transcription factor NF-κB according to previous evidence from both animal models and studies with human cells [4] [5] [6] . Since NF-κB represents a key element in several inflammatory pathways [7] , imatinib could be helpful to modulate host immune response against SARS-CoV-2. This is particularly noteworthy given that hyperinflammation plays a central role in severe COVID-19 [3, 8] . In addition, imatinib has shown in vitro antiviral activity against severe acute respiratory syndr ome a nd Middle East respiratory syndrome coronaviruses [9] , which are phylogenetically related to SARS-CoV-2 [10] . In this sense, ABL2 appears to be involved in the virus -cell fusion process, so its blockage could modulate the entry of coronaviruses into host cells [9] . These data also suggest that imatinib might be useful in early stages of SARS-CoV-2 infection, although further research is needed to ascertain the antiviral properties of this drug in COVID-19. To our knowledge, this is the first reported case of SARS-CoV-2 infection successfully treated with imatinib. However, elucidating the relevance of any therapeutic intervention from a single case report is always controversial since clinical outcomes may be influenced by some confounding factors such as the concomitant use of other therapies . Nevertheless, taking into account all the above mentioned data, we believe that imatinib should be considered a potential treatment for COVID-19. No external funding was received. * The value was above the reference range. † The value was below the reference range. Novel Coronavirus (2019 -nCoV) Situation Report -51 Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic San Martín-López, Imatinib might constitute a treatment option for lung involvement in COVID-19 Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury The tyrosine kinase inhibitor imatinib prevents lung injury and death after intravenous LPS in mice Imatinib treatment inhibit IL-6, IL-8, NFKB and AP-1 production and modulate intracellular calcium in CML patients COVID-19: Immunology and treatment options Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle J o u r n a l P r e -p r o o f Journal Pre-proof East respiratory syndrome coronavirus fusion Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding